DBV Technologies
Develops epicutaneous immunotherapy (EPIT) patch technology for food allergies.
DBV | PA
Overview
Corporate Details
- ISIN(s):
- FR0010417345 (+3 more)
- LEI:
- 969500PVBQFWQKVDMD80
- Country:
- France
- Address:
- 107 AVENUE DE LA REPUBLIQUE, 92320 CHATILLON
- Sector:
- Manufacturing
Description
DBV Technologies is a clinical-stage biopharmaceutical company developing treatments for food allergies and other immunological diseases. The company's core technology is Viaskin®, a proprietary investigational platform based on epicutaneous immunotherapy (EPIT). This non-invasive patch technology is designed to re-educate the immune system by delivering minimal amounts of antigens through intact skin. DBV's lead product candidate, Viaskin Peanut (DBV712), is in late-stage clinical development for the treatment of peanut allergies in pediatric patients. The development pipeline also includes Viaskin Milk (DBV135) for milk allergies, with the platform holding potential for applications beyond food allergies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2019-06-26 07:30 |
DBV Technologies Announces Appointment of Pharis Mohideen, M.D., as Chief Medic…
|
English | 179.0 KB | ||
| 2019-06-26 07:30 |
DBV Technologies annonce la nomination du Docteur Pharis Mohideen au poste de D…
|
French | 190.3 KB | ||
| 2019-06-11 14:00 |
Information mensuelle relative au nombre total des droits de vote et d’actions …
|
French | 96.8 KB | ||
| 2019-06-11 14:00 |
Monthly information regarding the total number of voting rights and total numb…
|
English | 86.9 KB | ||
| 2019-06-03 07:30 |
DBV Technologies invitée à présenter lors de prochaines conférences Investisseu…
|
French | 165.2 KB | ||
| 2019-06-03 07:30 |
DBV Technologies to Attend Upcoming Investor Conferences
|
English | 157.6 KB | ||
| 2019-06-01 14:00 |
DBV Technologies : présentation de données sur l’immunothérapie épicutanée au c…
|
French | 194.5 KB | ||
| 2019-06-01 14:00 |
DBV Technologies to Present Data from Epicutaneous Immunotherapy at EAACI 2019
|
English | 162.5 KB | ||
| 2019-05-24 22:30 |
DBV Technologies annonce les résultats de son Assemblée générale ordinaire et e…
|
French | 158.9 KB | ||
| 2019-05-24 22:30 |
DBV Technologies Announces Results of its 2019 Ordinary and Extraordinary Gener…
|
English | 137.5 KB | ||
| 2019-05-14 07:30 |
DBV Technologies Annonce le Départ de son Directeur Général Délégué, David Schi…
|
French | 158.3 KB | ||
| 2019-05-14 07:30 |
DBV Technologies Announces Departure of Deputy CEO David Schilansky
|
English | 162.9 KB | ||
| 2019-05-06 09:30 |
Ordinary and Extraordinary General Meeting of May 24, 2019 - Procedures for Obt…
|
English | 155.7 KB | ||
| 2019-05-06 09:30 |
Assemblée Générale Mixte du 24 mai 2019 - Modalités de mise à disposition des d…
|
French | 154.1 KB | ||
| 2019-05-03 23:30 |
Communiqué de presse - Modalités de mise à disposition des documents préparatoi…
|
French | 154.1 KB |
Automate Your Workflow. Get a real-time feed of all DBV Technologies filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for DBV Technologies
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for DBV Technologies via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-06-09 | N/A | Other | Other | 2,483,161 | 7,449,483.00 EUR |
Peer Companies
